44 related articles for article (PubMed ID: 15853706)
1. Computer aided screening of inhibitors to 5-α reductase type 2 for prostate cancer.
Bhattacharjee B; Talambedu U; Sadegh S; Goyal AK; Pande V; Nagaveni MB; Patil VM; Jayadev J; Middha SK
Bioinformation; 2011; 6(7):262-5. PubMed ID: 21738326
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.
Cabeza M; Sánchez-Márquez A; Garrido M; Silva A; Bratoeff E
Curr Med Chem; 2016; 23(8):792-815. PubMed ID: 26861003
[TBL] [Abstract][Full Text] [Related]
3. Steroidal antiandrogens and 5alpha-reductase inhibitors.
Bratoeff E; Ramírez E; Murillo E; Flores G; Cabeza M
Curr Med Chem; 1999 Dec; 6(12):1107-23. PubMed ID: 10519917
[TBL] [Abstract][Full Text] [Related]
4. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
5. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological evaluation of new 16-methyl pregnane derivatives.
Ramirez E; Cabeza M; Heuze I; Gutiérrez E; Bratoeff E; Membrillo M; Lira A
Chem Pharm Bull (Tokyo); 2002 Jan; 50(1):15-20. PubMed ID: 11824579
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the chemistry and pharmacological activity of new steroidal antiandrogens and 5 alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Ramirez E; Heuze Y; Flores E
Curr Med Chem; 2005; 12(8):927-43. PubMed ID: 15853706
[TBL] [Abstract][Full Text] [Related]
8. Steroid 5alpha-reductase inhibitors.
Flores E; Bratoeff E; Cabeza M; Ramirez E; Quiroz A; Heuze I
Mini Rev Med Chem; 2003 May; 3(3):225-37. PubMed ID: 12570838
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological options for treatment of hyperandrogenic disorders.
Reismann P; Likó I; Igaz P; Patócs A; Rácz K
Mini Rev Med Chem; 2009 Aug; 9(9):1113-26. PubMed ID: 19689407
[TBL] [Abstract][Full Text] [Related]
10. The enzyme and inhibitors of 4-ene-3-oxosteroid 5 alpha-oxidoreductase.
Li X; Chen C; Singh SM; Labrie F; Labire F [corrected to Labrie F]
Steroids; 1995 Jun; 60(6):430-41. PubMed ID: 7676475
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
